<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609059</url>
  </required_header>
  <id_info>
    <org_study_id>M201-A-CT-002</org_study_id>
    <nct_id>NCT04609059</nct_id>
  </id_info>
  <brief_title>First-in-Patient Study for Sing le Dose of M201-A Hydrochloride Injection in Japanese Patients With Paroxysmal Atrial Fibrillation</brief_title>
  <official_title>First-in-Patient Study for Sing le Dose of M201-A Hydrochloride Injection in Japanese Patients With Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kitasato University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aetas Pharma Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kitasato University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-in-Patient Study for sing le dose of M201-A hydrochloride injection in Japanese&#xD;
      patients with paroxysmal atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>throughout the study duration(up to day7)</time_frame>
    <description>Safety investigation based on combined Investigator examination, Adverse Events (particulary, incidence of abnormal laboratory tests,abnormal vital sings,abnormal 12-lead ECG, abnormal 24-hour Holter ECG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arrest of atrial fibrillation (AF)</measure>
    <time_frame>throughout the study duration(Within 2 hours)</time_frame>
    <description>Ratio of arrested AF* in administered subjects within 2 hours after administration (*Restoration of sinus rhythm should be kept at least one(1) minute or more.)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>M201-A Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Substance: M201-A Route of administration: continuous intravenous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Placebo for M201-A Route of administration: continuous intravenous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M201-A Injection</intervention_name>
    <description>Active Substance: M201-A Route of administration: continuous intravenous injection&#xD;
Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)</description>
    <arm_group_label>M201-A Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline Placebo: M201-A Placebo Route of administration: continuous intravenous injection&#xD;
Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) Japanese (male, female) adult with symptomatic paroxysmal atrial fibrillation (AF)&#xD;
&#xD;
          -  Written informed consent must be obtained on a voluntary basis before any assessment&#xD;
             is performed.&#xD;
&#xD;
             (2) Age: 20 to less than 85 years of age (3) Weight: 40 kilograms(kg) or more BMI:&#xD;
             18.5 to less than 28.0 on screening examination(screening) (4) Past AF History:&#xD;
             Event(s) as symptomatic AF with (at least) 2 hours or more AF lasting has (have)&#xD;
             occurred at least once or more a half year (6 months) prior to the screening.&#xD;
&#xD;
             (5) Occurrence time of the latest AF: Record(s) of the patient portable&#xD;
             electrocardiograph shows evidence to support that the latest AF has occurred within 3&#xD;
             hours to less than 3 days (72 hours) prior to an administration of the investigational&#xD;
             product.&#xD;
&#xD;
             (6) The AF lasting prior to the administration: 12 lead electrocardiogram just prior&#xD;
             to the administration shows that AF has not stopped.&#xD;
&#xD;
             (7) Excluded medication: Based on propositions of a principal investigator or a&#xD;
             co-investigator(s), a patient can consent for discontinuation of below antiarrhythmic&#xD;
             agents (the Vaughan-Williams classification) for at least 7 days after administration&#xD;
             since an advanced registration. Nonetheless, if a period between the advanced&#xD;
             registration and the administration is less than 7 days, it should be confirmed those&#xD;
             agent has unadministered during 7 days prior to the administration.&#xD;
&#xD;
        [Vaughan-Williams classification] Antiarrhythmic drug group I Antiarrhythmic drug group III&#xD;
        Antiarrhythmic drug group IV Bepridil (8) Excluded administration of amiodarone: It should&#xD;
        be confirmed that amiodarone hydrochloride is not unadministered within one (1) year before&#xD;
        the screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) Heart failure (NYHA II, III, IV). Excluding palpitations induced by atrial&#xD;
             fibrillation (AF) (2) Any atrioventricular block of first, second or third degree at&#xD;
             the time of sinus rhythm (3) Any risk factor leads to Torsades de Pointes (TdP)&#xD;
&#xD;
               1. [0]: 440 ms or more in standard 12-lead electrocardiogram at the time of sinus&#xD;
                  rhythm within 3 months prior to administration&#xD;
&#xD;
               2. Hypokalemia or suspected to be hypokalemia:&#xD;
&#xD;
                  One or more of serum potassium levels, obtained at any time during 6 months in&#xD;
                  advance of administration including pre-administration examination, has been 3.6&#xD;
                  [1]/L or less.&#xD;
&#xD;
               3. Hypomagnesemia or suspected be hypomagnesemia: One or more of serum magnesium&#xD;
                  levels, obtained at any time during 6 months in advance of administration&#xD;
                  including pre-administration examination, has been 1.8 mg/dL or less.&#xD;
&#xD;
               4. T-wave abnormality of electrocardiogram at the time of sinus rhythm&#xD;
&#xD;
               5. Past medical history as fainting; syncope with unknown etiology or complicating&#xD;
                  illness.&#xD;
&#xD;
               6. Past own medical history or family medical history as long QT syndrome (4) Severe&#xD;
                  heart hypertrophy; Cardiomegaly: Septal Thickness of cardiac ultrasound has been&#xD;
                  exceeded over 15 mm.&#xD;
&#xD;
                  (5) Left atrial dimension (parasternal long-axis view) of cardiac ultrasound has&#xD;
                  been exceeded over 45 mm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Miwa Nonaka</last_name>
    <phone>+81357916398</phone>
    <email>m201-a@insti.kitasato-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Koga general Hospital</name>
      <address>
        <city>Koga-City</city>
        <state>Ibaraki</state>
        <zip>306-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koji Uchida</last_name>
      <phone>+81280471010</phone>
      <email>uchida@kogahosp.jp</email>
    </contact>
    <investigator>
      <last_name>Masataka Fukue</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tetsuya Ishikawa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital</name>
      <address>
        <city>Sagamihara-city</city>
        <state>Kanagawa</state>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimiko Yamamura</last_name>
      <phone>ï¼‹81427788462</phone>
      <email>kimiko-y@kitasato-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Junya Ako</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Takao Shimohama</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hidehira Fukaya</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Kishihara</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Oikawa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naruya Ishizue</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sendai Cardiovascular Center</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi</state>
        <zip>981-3133</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masahiro Yagi</last_name>
      <phone>+81223721111</phone>
      <email>ccuami@star.gmobb.jp</email>
    </contact>
    <investigator>
      <last_name>Masahiro Yagi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tatsuro Uchida</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shinya Fujii</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hiroshi Kobayashi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shoko Uematsu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chikahiko Koeda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yukako Tanaka</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Satoshi Miyazawa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryozo Maeda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>JIHAENG Im</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University Saitama Medical Center</name>
      <address>
        <city>Koshigaya-city,</city>
        <state>Saitama</state>
        <zip>343-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariko Iyama</last_name>
      <phone>+81489650658</phone>
      <email>m-iyama@dokkyomed.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Shiro Nakahara</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reiko Fukuda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naoki Nishiyama</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuri Koshikawa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomoaki Ukaji</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yamanashi Prefectural Central Hospital</name>
      <address>
        <city>Kofu-city</city>
        <state>Yamanashi</state>
        <zip>400-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masahiko Nakamura</last_name>
      <phone>+81552537111</phone>
      <email>m-nakamura@ych.pref.yamanashi.jp</email>
    </contact>
    <investigator>
      <last_name>Masahiko Nakamura</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ken Umetani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keita Sano</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aritaka Makino</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Toshiaki Yano</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Takuya Shimizu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serina Ono</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chisa Asahina</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Koki Fukasawa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miu Eguchi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kitasato University</investigator_affiliation>
    <investigator_full_name>Yuji KUMAGAI</investigator_full_name>
    <investigator_title>Yuji KUMAGAI, Professor, Kitasato University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

